Life Sciences Snapshot – Q4 2024 – A Quarterly Report on Financing Trends
14 minute read | December.20.2024
Partner
Boston
Albert Vanderlaan leads Orrick’s Capital Markets practice. He counsels public and private companies, investment banks, venture capital firms, SPACs and SPAC sponsors focused on the high-growth technology and life sciences sectors. Albert advises these clients on a variety matters, including securities offerings, securities law compliance and corporate governance matters.
Albert is involved in a broad range of corporate legal engagements for high growth technology companies, including IPOs, follow-on public offerings, private and public company securities law compliance matters, public company disclosure obligations, de-SPAC transactions, SPAC IPOs, venture financings and mergers and acquisitions. He also regularly advises public and private companies and their boards of directors on corporate governance issues.
Albert's clients include public and private companies in technology, automotive, Internet related industries, real estate, finance and the life sciences (including, among others, immuno-oncology, gene therapy, restorative cell therapy and medical device companies). He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.
Albert was named to the Deal’s Top Rising Stars 2021 list, which recognizes top new partners at U.S. law firms who are “doing spectacular work in the field of deal-making and who have continued to progress in their career despite the obstacles put in front of them.”
Prior to joining Orrick, Albert was an attorney with Gunderson Dettmer and Cooley.
Albert's engagements include:
*Please note: Albert's experience includes that prior to joining Orrick.
14 minute read | December.20.2024
October.09.2024 - October.10.2024
June.26.2024